Belfast Health and Social Care Trust
caring supporting improving together

FOI/30562

4 March 2024

Targeted Medications within Dermatology and Respiratory Medicine

1. **How many patients were treated in January 2024 (or latest available month) by the Dermatology department with the following drugs:**

- **Abrocitinib (Cibinqo)** 6
- **Baricitinib (Olumiant)** <5
- **Dupilumab (Dupixent)** 155
- **Lebrikizumab (Ebglyss)** <5
- **Omalizumab (Xolair)** 31
- **Tralokinumab (Adtralza)** <5
- **Upadacitinib (Rinvoq)** 26

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. **How many patients were treated in January 2024 (or latest available month) by the Respiratory Medicine department with the following drugs:**

- **Benralizumab (Fasenra)** 102
- **Dupilumab (Dupixent)** 67
- **Mepolizumab (Nucala)** 239
- **Omalizumab (Xolair)** 23
- **Reslizumab (Cinqaero)** 0
- **Tezepelumab (Tezspire)** 7

For clarification, this is the number of patients and not the number of biologicals given as some re-administered 2-weekly.